Now that we have been relegated to a marketing company we can...

First 5 Last

Greenthumb2

127 Posts.

29/09/16

23:13

Post #: 19523756

Now that we have been relegated to a marketing company we can probably get rid of some of the board to help reduce cash burn further!!

Column 1

0 Sunshine Heart Announces Strategic Realignment EDEN PRAIRIE, Minn., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (NASDAQ:SSH) today announced that it is implementing a strategic realignment of its near term strategy to fully focus the Company's resources on its recently acquired Aquadex FlexFlow® System. The Aquadex system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization."Aquadex was an important strategic investment, which allows Sunshine Heart to strengthen its presence in the heart failure market," said John Erb, Sunshine's Chairman and CEO. "We have been very pleased with the reception and enthusiasm we have received from many current and former Aquadex customers that depend on Aquapheresis® Therapy to manage fluid overload, including patients with congestive heart failure. Aquadex has shown to help reduce the length of stay while in the hospital and the number of unscheduled hospital visits in total."Key elements of the Company's near-term strategy include:

Pausing clinical evaluations of the neuromodulation technology

Reducing cash burn from $2 million per month in the fourth quarter of 2015 to a targeted cash burn of $800,000 per month in fourth quarter of 2016

Continuing the Company's ongoing review of potential partnerships, strategic alliances, and the pursuit of financing alternatives.

The above measures will help the Company to attain targeted fourth quarter 2016 annualized revenue run-rate for the Aquadex business of $5 million and fourth quarter 2017 annualized revenue run-rate for the Aquadex business of $10 million.

	Column 1
0	Sunshine Heart Announces Strategic Realignment EDEN PRAIRIE, Minn., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (NASDAQ:SSH) today announced that it is implementing a strategic realignment of its near term strategy to fully focus the Company's resources on its recently acquired Aquadex FlexFlow® System. The Aquadex system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization."Aquadex was an important strategic investment, which allows Sunshine Heart to strengthen its presence in the heart failure market," said John Erb, Sunshine's Chairman and CEO. "We have been very pleased with the reception and enthusiasm we have received from many current and former Aquadex customers that depend on Aquapheresis® Therapy to manage fluid overload, including patients with congestive heart failure. Aquadex has shown to help reduce the length of stay while in the hospital and the number of unscheduled hospital visits in total."Key elements of the Company's near-term strategy include: Pausing clinical evaluations of the neuromodulation technology Reducing cash burn from $2 million per month in the fourth quarter of 2015 to a targeted cash burn of $800,000 per month in fourth quarter of 2016 Continuing the Company's ongoing review of potential partnerships, strategic alliances, and the pursuit of financing alternatives. The above measures will help the Company to attain targeted fourth quarter 2016 annualized revenue run-rate for the Aquadex business of $5 million and fourth quarter 2017 annualized revenue run-rate for the Aquadex business of $10 million.